ACC Inhibitor and PPAR Agonist Combination for NAFLD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-alcoholic fatty liver disease (NAFLD) are inadequate in effectively stabilizing or lessening the severity or progression of the condition, particularly in addressing associated hypertriglyceridemia and non-alcoholic steatohepatitis (NASH), with existing therapies often failing to manage these aspects comprehensively.
Innovation Solution
Administering an Acetyl-CoA carboxylase (ACC) inhibitor, such as Compound 1 or Compound 2, in combination with a peroxisome proliferator-activated receptor alpha (PPARα) agonist or fish oil to patients, which helps in treating, stabilizing, or lessening the severity of NAFLD and NASH while reducing or eliminating hypertriglyceridemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat NAFLD, then some treatment effect is achieved, but they fail to comprehensively manage hypertriglyceridemia and NASH
Solution Approach 1:
The patent combines an ACC inhibitor with a PPARα agonist or fish oil to create a multi-functional therapy that simultaneously addresses NAFLD, hypertriglyceridemia, and NASH. This combination approach merges the benefits of both agents to achieve comprehensive management of the disease spectrum and its associated metabolic abnormalities.
Solution Approach 2:
The combination therapy is designed to perform multiple functions: treating NAFLD, reducing liver fat accumulation, managing hypertriglyceridemia, and treating NASH. The ACC inhibitor and PPARα agonist/fish oil work together to provide universal coverage across the full spectrum of metabolic liver diseases and associated conditions.
2Quantity of substance
If ACC inhibitor is administered alone, then liver fat accumulation is reduced, but hypertriglyceridemia may worsen
Solution Approach 1:
The patent uses the PPARα agonist or fish oil to counteract the potential harmful effect of ACC inhibitor-induced hypertriglyceridemia. The PPARα agonist activates lipid metabolism pathways that reduce triglyceride production, thereby converting a potential adverse effect into a manageable condition and even a therapeutic opportunity.
Solution Approach 2:
The combination of ACC inhibitor with PPARα agonist or fish oil provides preliminary counter-action against potential hypertriglyceridemia. By administering both agents together, the patent preemptively addresses the risk of triglyceride elevation before it becomes a clinically significant problem.
3Object-generated harmful factors
If PPARα agonist is used to reduce triglycerides, then hypertriglyceridemia is managed, but liver fat reduction may be insufficient
Solution Approach 1:
The patent divides the therapeutic task into two complementary segments: the ACC inhibitor specifically targets liver fat accumulation by inhibiting fatty acid synthesis, while the PPARα agonist separately targets triglyceride metabolism. This segmentation allows each agent to optimize its specific function without compromising the other.
Solution Approach 2:
The combination therapy changes multiple metabolic parameters simultaneously: the ACC inhibitor reduces de novo lipogenesis and liver fat content, while the PPARα agonist enhances fatty acid oxidation and reduces circulating triglycerides. This multi-parameter approach achieves comprehensive metabolic improvement.
Data Source
AI summary
The present disclosure provides methods and compositions for treating, stabilizing or lessening the severity or progression of a non-alcoholic fatty liver disease.